Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2023 | Story Andre Damons | Photo Charl Devenish
Dr Emms
Dr Ayodeji Emmanuel Ogunbayo (right), who graduated this week with a Doctor of Philosophy degree with specialisation in Medical Virology, with his proud supervisor Prof Martin Nyaga, Associate Professor in the UFS Next Generation Sequencing (UFS-NGS).

With respiratory diseases contributing to the highest morbidity and mortality rate in children, and the vast majority of disease aetiology remaining undiagnosed in clinical settings, Dr Ayodeji Emmanuel Ogunbayo hopes his research for his PhD in Medical Virology will help to reduce mortality in children with respiratory infection.

Dr Ogunbayo, commonly known as Dr Emms by his peers, graduated on Thursday (20 April 2023) with a Doctor of Philosophy degree with specialisation in Medical Virology at the University of the Free State (UFS) Faculty of Health Sciences graduation ceremony. The title of his thesis was Metagenomics of the respiratory RNA virome of children in the Free State. His supervisor was Prof Martin Nyaga, Associate Professor in the UFS Next Generation Sequencing (UFS-NGS) and Director of the WHO Collaborating Centre (WHO CC).

“While clinical metagenomics next-generation sequencing (mNGS), which is an upcoming method, has the potential to revolutionise infection diagnosis and management in children, there is a dearth of information on its clinical applicability in Africa. This is the knowledge that guided the inception of this research,” says Dr Ogunbayo.

Project came at the right time

He commenced with his PhD in Medical Virology in 2019, which was centred on the applicability of mNGS in severe acute respiratory infection (SARI) in children and deciphering the children’s respiratory virome in health and disease, a project which was the first of its kind in Africa.

According to him, the project was conceived before the COVID-19 pandemic, however, despite the challenges encountered due to lockdown measures, the project came at the right time as it was able to address several profound effects of the pandemic such as COVID-19 on the dynamics of transmission of respiratory viruses and ultimately its effect on children’s health. During his PhD study, he published four manuscripts in highly reputable journals including the most recent one which was accepted in Journal of Medical Virology (JMV)  an impressive impact factor of 20.693.

The findings from this study included a validated and robust workflow to recover respiratory RNA viruses from clinical samples, according to the graduation programme. The established workflow was adapted to decipher children’s respiratory virome composition in health and disease, with a degree of heterogeneity, while simultaneously establishing the clinical diagnostic applicability of mNGS and, more importantly, the increased utility of dual-triple mNGS analysis tools in robust detection of viral pathogens in SARI.

His hope for the research

Dr Ogunbayo says: “This research generated vast pioneering information and data in Africa that could guide and influence policy in the adoption of clinical metagenomics, especially in cases where conventional methods of diagnosis yielded no results. Hopefully, this could lessen mortality due to respiratory infection in children.

Before studying in the field of medical Microbiology and Virology, he wanted to be a psychiatric nurse, but instead chose his current field of study because of his interest in the microbial world and pathology.

“It’s a feeling one cannot really put into words. A part of me feels like it is a ‘dream come true’ and another part of me feels like ‘this is a milestone achieved, but it’s just a stepping stone to further milestones to be achieved’.

“What is next is for me to dive into the world of policy-influencing research, give back to the academic community through student supervision, and work on my journey to becoming an emerging researcher. This is the reason I have taken a postdoctoral position at the UFS-NGS Unit under the mentorship of Prof Martin Nyaga.”

Prof Nyaga says: “Looking back at Emmanuel’s doctoral journey, it brought out the best in him in every aspect of the study. Longitudinal studies are hectic in the sampling phase, and all the ethical clearances that a study must achieve prior to beginning the sampling and the laboratory work can be very frustrating. Soon after his study was approved, the pandemic lockdown level 5 rules were applied, which meant he had to pause on the study. However, his focus, positive mindset and his ability to work in close consultation with his supervisor enabled him to finish this study in the best way possible. I am very proud of him.”

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept